The Expressional Pattern of Invasion-Related Extracellular Matrix Molecules in CNS Tumors

References

• Klekner A, Virga J, Toth J, Hortobagyi T, Der A, Szemcsak C, et al. The role of extracellular matrix components in the invasion of intracranial malignancies. Magy Onkol. Hungary. 2013;57(4):222–231.
   PubMedGoogle Scholar
• Claes A, Idema AJ, Wesseling P. Diffuse glioma growth: a guerilla war. Acta Neuropathol.. 2007;114(5):443–458.
   PubMed Web of Science ®Google Scholar
• LemCrossed D, Signe JM, Clavreul A, Menei P. Intratumoral heterogeneity in glioblastoma: don’t forget the peritumoral brain zone. Neuro Oncol. 2015;17(10):1322–1332.
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al. CBTRUS Statistical Report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro-Oncology [Internet]. 2014;16(4):iv1–iv63. Available from: http://neuro-oncology.oxfordjournals.org/content/16/suppl_4/iv1.short
   PubMedGoogle Scholar
• Goodenberger ML, Jenkins RB. Genetics of adult glioma. Cancer Genet [Internet]. 2012;205(12):613–621. Available from: http://www.sciencedirect.com/science/article/pii/S2210776212002608
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol [Internet]. 2016;131(6):803–820. Available from: http://link.springer.com/10.1007/s00401-016-1545-1
   PubMed Web of Science ®Google Scholar
• Pouratian N, Schiff D. Management of low-grade glioma. Curr Neurol Neurosci Rep. 2010;10(3):224–231.
   PubMed Web of Science ®Google Scholar
• Markert JM. The role of early resection vs Biopsy in the management of low-grade gliomasearly vs late surgery in low-grade gliomas. JAMA [Internet]. 2012;308(18):1918–1919. Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=23099540&retmode=ref&cmd=prlinks%5Cnpapers3://publication/doi/10.1001/jama.2012.14523
   Google Scholar
• van den Bent MJ, Snijders TJ, Bromberg JEC. Current treatment of low grade gliomas. Memo. 2012;5(3):223–227. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3458190&tool=pmcentrez&rendertype=abstract
   PubMedGoogle Scholar
• Pedersen CL, Romner B. Current treatment of low grade astrocytoma: a review. Clin Neurol and Neurosurg Netherlands. 2013;115(1):1–8.
   PubMed Web of Science ®Google Scholar
• Lind-Landström T, Habberstad AH, Sundstrøm S, Torp SH. Prognostic value of histological features in diffuse astrocytomas WHO grade II. Int J Clin Exp Pathol. 2012;5(2):152–158.
   PubMed Web of Science ®Google Scholar
• Klekner A, Varga I, Bognár L, Hutóczki G, Kenyeres A, Tóth J, et al. Extracellular matrix of cerebral tumors with different invasiveness. Ideggyogy Sz. 2010;63(1–2):38–43.
   PubMedGoogle Scholar
• Bouterfa H, Darlapp AR, Klein E, Pietsch T, Roosen K, Tonn JC. Expression of different extracellular matrix components in human brain tumor and melanoma cells in respect to variant culture conditions. J Neurooncol [Internet]. 1999;44(1):23–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10582665
   PubMed Web of Science ®Google Scholar
• Chintala SK, Rao JK. Invasion of human glioma: role of extracellular matrix proteins. Front Biosci. 1996;1:d324–d339.
   PubMedGoogle Scholar
• Petrás M, Hutóczki G, Varga I, Vereb G, Szöllősi J, Bognár L, et al. Expression pattern of invasion-related molecules in cerebral tumors of different origin. Magyar Onkológia. 2009;53(3):253–258.
   PubMedGoogle Scholar
• Zamecnik J, Vargova L, Homola A, Kodet R, Sykova E. Extracellular matrix glycoproteins and diffusion barriers in human astrocytic tumours. Neuropathol Appl Neurobiol. 2004;30(4):338–350.
   PubMed Web of Science ®Google Scholar
• Varga I, Hutóczki G, Szemcsák CD, Zahuczky G, Tóth J, Adamecz Z, et al. Brevican, neurocan, tenascin-C and versican are mainly responsible for the invasiveness of low-grade astrocytoma. Pathol Oncol Res. 2012;18(2):413–420.
   PubMed Web of Science ®Google Scholar
• Klekner Á, Hutóczki G, Virga J, Reményi-Puskár J, Tóth J, Scholtz B, et al. Expression pattern of invasion-related molecules in the peritumoral brain. Clin Neurol Neurosurg. 2015;139:138–143.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Matsuda Y, Naito Z, Ishiwata T. CD44 in human glioma correlates with histopathological grade and cell migration. Pathol Int. 2012;62(7):463–470.
   PubMed Web of Science ®Google Scholar
• Pollo B. Pathological classification of brain tumors. Quart J Nuc Med Mol Imag. 2012;56:103–111.
   PubMed Web of Science ®Google Scholar
• Johnson JD, Young B. Demographics of brain metastasis. Neurosurg Clin N Am [Internet]. 1996;7(3):337–344. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8823767
   PubMed Web of Science ®Google Scholar
• Fox BD, Cheung VJ, Patel AJ, Suki D, Rao G. Epidemiology of metastatic brain tumors. Neurosurg Clin N Am.. 2011;22(1):1–6. Vol.
   PubMed Web of Science ®Google Scholar
• Fisher JL, Schwartzbaum JA, Wrensch M, Wiemels JL. Epidemiology of brain tumors [Review]. Neurol Clin. 2007;25(4):867.
   PubMed Web of Science ®Google Scholar
• Varga I, Hutóczki G, Petrás M, Scholtz B, Mikó E, Kenyeres A, et al. Expression of invasion-related extracellular matrix molecules in human glioblastoma versus intracerebral lung adenocarcinoma metastasis. Cen Eur Neurosurg. 2010;71(04):173–180. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20397122
   PubMedGoogle Scholar
• Takeichi M. Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol [Internet]. 1993;5(5):806–811. Available from: http://www.sciencedirect.com/science/article/pii/095506749390029P
   PubMed Web of Science ®Google Scholar
• Patarroyo M, Tryggvason K, Virtanen I. Laminin isoforms in tumor invasion, angiogenesis and metastasis. Semin Cancer Biol [Internet]. 2002;12(3):197–207. Available from: http://www.sciencedirect.com/science/article/pii/S1044579X02000238
   PubMed Web of Science ®Google Scholar
• Wegrowski Y, Maquart F-X. Chondroitin sulfate proteoglycans in tumor progression. Adv Pharmacol [Internet]. 2006;53:297–321. Available from: http://www.sciencedirect.com/science/article/pii/S105435890553014X
   Google Scholar
• Kurtkaya-Yapicier ? ?, Scheithauer B, Woodruff JM. The pathobiologic spectrum of Schwannomas. Histology and Histopathology. 2003;18:925–934.
   PubMed Web of Science ®Google Scholar
• Fong B, Barkhoudarian G, Pezeshkian P, Parsa AT, Gopen Q, Yang I. The molecular biology and novel treatments of vestibular schwannomas. J Neurosurg [Internet]. 2011;115(5):906–914. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21800959
   PubMed Web of Science ®Google Scholar
• Stangerup S-E, Caye-Thomasen P. Epidemiology and natural history of vestibular schwannomas. Otolaryngol Clin North Am [Internet]. 2012;45(2):257–268. Available from: http://dx.doi.org/10.1016/j.otc.2011.12.008
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–408.
   PubMed Web of Science ®Google Scholar
• Bradford M. Rapid and sensitive method for quantification of microgram quantities of protein utilizing principle of protein-dye-binding. Anal Biochem. 1976;72(1–2):248–254.
   PubMed Web of Science ®Google Scholar
• Lange V, Picotti P, Domon B, Aebersold R. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol. 2008;4:222.
   PubMed Web of Science ®Google Scholar
• James A, Jorgensen C. Basic design of MRM assays for peptide quantification. Methods Mol Biol. 2010;658:167–185.
   PubMedGoogle Scholar
• Iuga C, Seicean A, Iancu C, Buiga R, Sappa PK, Völker U, et al. Proteomic identification of potential prognostic biomarkers in resectable pancreatic ductal adenocarcinoma. Proteomics. Wiley Proteomics.. 2014;14(7–8):945–955.
   PubMed Web of Science ®Google Scholar
• Qian W-J, Jacobs JM, Liu T, Camp DG, Smith RD. Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications. Mol Cell Proteomics. 2006;5(10):1727–1744.
   PubMed Web of Science ®Google Scholar
• Wei K-C, Huang C-Y, Chen P-Y, Feng L-Y, Wu T-WE, Chen S-M, et al. Evaluation of the prognostic value of CD44 in glioblastoma multiforme. Anticancer Res. 2010;30(1):253–259.
   PubMed Web of Science ®Google Scholar
• Ranuncolo SM, Ladeda V, Specterman S, Varela M, Lastiri J, Morandi A, et al. CD44 expression in human gliomas. J Surg Oncol. 2002;79(1):30–35.
   PubMed Web of Science ®Google Scholar
• Delpech B, Maingonnat C, Girard N, Chauzy C, Olivier A, Maunoury R, et al. Hyaluronan and hyaluronectin in the extracellular matrix of human brain tumour stroma. Eur J Cancer. 1993;29(7):1012–1017.
   Google Scholar
• Novak U, Stylli SS, Kaye AH, Lepperdinger G. Hyaluronidase-2 overexpression accelerates intracerebral but not subcutaneous tumor formation of murine astrocytoma cells. Cancer Res. 1999;59(24):6246–6250.
   PubMed Web of Science ®Google Scholar
• Zoltan-Jones A, Huang L, Ghatak S, Toole BP. Elevated hyaluronan production induces mesenchymal and transformed properties in epithelial cells. J Biol Chem. 2003;278(46):45801–45810.
   PubMed Web of Science ®Google Scholar
• Park JB, Kwak HJ, Lee SH. Role of hyaluronan in glioma invasion. Cell Adh Migr. 2008;2(3):202–207. Vol.
   PubMed Web of Science ®Google Scholar
• Färber K, Synowitz M, Zahn G, Vossmeyer D, Stragies R, van Rooijen N, Kettenmann H. An alpha5beta1 integrin inhibitor attenuates glioma growth. Mol Cell Neurosci [Internet]. 2008;39(4):579–585. Available from: http://www.sciencedirect.com/science/article/pii/S1044743108002212
   PubMed Web of Science ®Google Scholar
• D’Abaco GM, Kaye AH. Integrins: molecular determinants of glioma invasion. J Clin Neurosci [Internet]. 2007;14(11):1041–1048. Available from: http://www.sciencedirect.com/science/article/pii/S0967586807003797
   PubMed Web of Science ®Google Scholar
• Tysnes BB, Larsen LF, Ness GO, Mahesparan R, Edvardsen K, Garcia-Cabrera I, Bjerkvig R. Stimulation of glioma-cell migration by laminin and inhibition by anti-alpha3 and anti-beta1 integrin antibodies. Int. J. Cancer. 1996;67(6):777–784. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-0029981104&partnerID=tZOtx3y1
   PubMed Web of Science ®Google Scholar
• Massagué J. TGFb in cancer. Cell [Internet]. 2008;134(2):215–230. Available from: http://dx.doi.org/10.1016/j.cell.2008.07.001
   Google Scholar
• Dong Z-Z, Yao D-F, Yao M, Qiu L-W, Zong L, Wu W, et al. Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int [Internet]. 2008;7(3):288–295. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18522884
   PubMed Web of Science ®Google Scholar
• Xie L, Law BK, Chytil AM, Brown K. A, Aakre ME, Moses HL. Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia [Internet]. 2004;6(5):603–610. Available from: http://dx.doi.org/10.1593/neo.04241
   PubMed Web of Science ®Google Scholar
• Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009;19(2):156–172. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19153598
   PubMed Web of Science ®Google Scholar
• Knepper JL, James AC, Ming JE. TGIF, a gene associated with human brain defects, regulates neuronal development. Dev Dyn. 2006;235(6):1482–1490.
   PubMed Web of Science ®Google Scholar
• Zhang M-Z, Ferrigno O, Wang Z, Ohnishi M, Prunier C, Levy L, et al. TGIF governs a feed-forward network that empowers wnt signaling to drive mammary tumorigenesis. Cancer Cell. 2015;27(4):547–560.
   PubMed Web of Science ®Google Scholar